An online survey of 298 Belgian antenatal care practitioners (obstetricians, midwives, GPs, fetal medicine specialists) conducted Sept–Nov 2024 to describe current practices in antenatal CMV testing, valaciclovir prescribing, and termination of pregnancy (TOP) decisions, in a setting where universal screening is not recommended and testing is not reimbursed.
89.4% of respondents reported ordering antenatal CMV testing despite no national recommendation or reimbursement; 51.7% of fetal medicine specialists prescribed valaciclovir routinely; TOP was reported to occur even without severe fetal involvement, and cost was the leading barrier to both testing and treatment.
Survey responses reflect self-reported perceptions rather than verified clinical records, introducing social desirability and recall bias; the sample was drawn from practitioners who chose to respond, risking selection bias; findings may not be representative of all Belgian practitioners or generalizable to other healthcare systems.
Given widespread off-guideline CMV testing and variable valaciclovir use, clinicians should be aware that practice is highly heterogeneous; updated national guidance and reimbursement policies are needed to standardize counseling—especially around TOP decisions in cases without severe fetal involvement.
Explore related topics